Amdocs (DOX) Cash & Equivalents (2009 - 2026)

Amdocs has disclosed Cash & Equivalents across 18 years of filings, most recently posting $214.5 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 13.3% year-over-year to $214.5 million; the TTM figure through Mar 2026 stood at $214.5 million (down 13.3% YoY), while the FY2025 annual figure was $325.0 million, down 6.09% from the prior year.
• Cash & Equivalents retreated to $214.5 million in Q1 2026, from $247.9 million in the prior quarter.
• Over the last five years, Cash & Equivalents for DOX reached as high as $623.4 million in Q1 2023 and fell as low as $213.8 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $346.1 million (2024), against an average of $401.4 million.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 44.99% — and 2025, when it rose 15.92%.
• A 5-year view of Cash & Equivalents shows it stood at $492.2 million in 2022, then slipped by 22.21% to $382.9 million in 2023, then sank by 44.15% to $213.8 million in 2024, then climbed by 15.92% to $247.9 million in 2025, then slipped by 13.47% to $214.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $214.5 million, $247.9 million, and $325.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.